ArticleInfectious diseases and therapy2026
Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antiretroviral therapy switch among Medicare beneficiaries with HIV.Journal of managed care & specialty pharmacy · 2026Article
- Antiretroviral Treatment Switch Among Treatment-Experienced People with HIV.Journal of health economics and outcomes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionAdherence to antiretroviral therapy (ART) is crucial for people with HIV (PWH) to maintain health. The Medicare program insures a substantial proportion of PWH in the United States; however, few studies have evaluated ART treatment patterns in this population. This study described treatment persistence and switch patterns among Medicare-insured PWH with low ART adherence or significant treatment gaps prior to re-initiating ART.
methodsA retrospective cohort study was conducted using data from Medicare Fee-For-Service and Medicare Advantage from January 2017 to December 2022. PWH aged ≥ 18 years with documented treatment experience receiving an index ART regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/lamivudine (DTG/3TC), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), or multi-tablet regimens (MTRs; dolutegravir + emtricitabine/tenofovir alafenamide [DTG + F/TAF] or dolutegravir + emtricitabine/tenofovir disoproxil fumarate [DTG + F/TDF]) were included. Study groups of interest included PWH with low adherence (defined as a proportion of days covered [PDC] < 85%) and PWH who had initiated index ART after a ≥ 90-day gap. Treatment nonpersistence (discontinuation or switch) and switch outcomes were evaluated using Kaplan-Meier curves and Cox proportional hazards models.
resultsOf 30,205 treatment-experienced PWH, 6140 had low adherence on the index regimen and 7227 had significant treatment gaps prior to re-initiating ART. In both groups, risk of treatment nonpersistence was significantly lower for PWH indexed on B/F/TAF versus DTG/ABC/3TC and MTRs but similar for DTG/3TC. Risk of treatment switch was lower for those indexed on B/F/TAF versus all other ART regimens evaluated (P < 0.01).
conclusionsAmong Medicare-insured PWH with low adherence or significant gaps in care, those receiving B/F/TAF had a lower risk of switch compared with other ART regimens. Optimizing ART selection to improve persistence and reduce treatment switching remains an important consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.